PURCHASE -
'The KOL roundtable we conducted featured a panel of Alzheimer's disease expert clinicians and researchers who highlighted the need to find Alzheimer's disease treatments that are less burdensome for patients and their care partners,' said
The KOLs shared their perspectives on the currently approved immunotherapies for early Alzheimer's disease, including perception of their effectiveness in targeting plaque, impact of amyloid related imaging abnormalities (ARIA) on commercial uptake, and the clinical meaningfulness of the reported changes in disease progression.
Dr. Porsteinsson agreed, noting 'a pretty remarkable clearance of A plaques with [the currently approved therapies].' However, he explained, 'even if the humanized monoclonal antibodies targeting beta amyloid plaques become well established, they won't meet the need of all patients with early symptomatic Alzheimer's disease.'
In addition to the direct engagement of A plaque, other processes that were discussed in the KOL event were neurodegeneration, neuroinflammation and neuro-regeneration, which are biological processes associated with Alzheimer's disease progression. In order to improve upon the outcomes observed with monoclonal antibody monotherapy, options may include drugs that address these secondary biological processes, which are driven by toxic aggregated A oligomers, oxidative stress and inflammation. Dr. Porsteinsson pointed to one such candidate, Cognition's CT1812, which he observed displaces 'oligomers or prevents them from binding to neurons, clears them to the cerebrospinal fluid and through that prevents the synaptic toxicity and the impact on neuronal function. In fact, in preclinical models of Alzheimer's disease, it was able to restore cognitive deficits.'
CT1812 is currently in Phase 2 clinical trials for Alzheimer's disease, including the START study for adults with MCI and early Alzheimer's, and the SHINE study for people with mild-to-moderate disease. The SHINE study enrolled participants in the
Dr. Vijverberg reviewed the design of the SHINE study and the results of the preliminary analysis of the first 24 patients who finished six months of treatment. 'We see in the 24 patients that we already analyzed that there was a three-point difference on the ADAS Cog 11.' He continued, 'Of course, it's preliminary, however together with the SEQUEL where we saw quick response in synaptic health, it's exciting to see cognition [going] in the right direction in this group of patients.'
Cognition expects to report topline results from the SHINE study in mid-2024.
About CT1812
CT1812 is an experimental orally delivered small molecule sigma-2 (-2) receptor modulator designed to penetrate the blood-retinal barrier and bind selectively and saturably to the -2 receptor complex. The -2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with soluble beta amyloid (A) oligomers, oxidative stress and other stressors. Cognition's clinical program will assess if regulating these processes by modulating the -2 receptor with CT1812 can maintain homeostatic function.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, the timing and expected results of our clinical trials and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the
Contact:
Email: cmcdonald@tiberend.com
Email: mmoyer@lifesciadvisors.com
(C) 2024 Electronic News Publishing, source